Search tips
Search criteria 


Logo of eurosurvEurosurveillance
Euro Surveill. 2017 March 16; 22(11): 30482.
PMCID: PMC5356422

Increasing evidence of tick-borne encephalitis (TBE) virus transmission, the Netherlands, June 2016


We present a case of endemic tick-borne encephalitis (TBE) occurring in June 2016 in the eastern part of the Netherlands in an area where a strain of TBE virus, genetically different from the common TBE virus strains in Europe, was reported in ticks in 2016. With the start of the tick season in spring, this second autochthonous Dutch TBE case should remind physicians to consider the possibility of endemic TBE in patients with respective symptoms.

Keywords: The Netherlands, vector-borne infections, zoonotic infections, viral infections, emerging or re-emerging diseases, tick-borne diseases, tick-borne encephalitis - TBE, Flaviviridae

We report the second autochthonous human case of tick-borne encephalitis (TBE) ever diagnosed in the Netherlands in an area where a strain of TBE virus, genetically different from the common TBE virus strains in Europe, was identified in ticks in 2016.

Case description

On 14 July 2016 (day 1), a 44 year-old male patient was admitted to the hospital with tinnitus, malaise, vomiting, muscle aches, and headache, that had started on 8 July. Shortly before symptom onset, starting on 25 June, he had also experienced a short episode of malaise and fever, from which he recovered spontaneously. A week before the first symptoms, he had been bitten by a tick, without having developed erythema migrans. The patient lives in the Sallandse heuvelrug area in the eastern part of the Netherlands, where tick-borne encephalitis virus (TBEV) had been detected in ticks in 2016 [1]. He maintains a garden in which he frequently encountered ticks. He also reported frequent outdoor activities such as running and walking in the area where he lived. Six weeks before the first symptoms, he had travelled to Bad Salzungen in Thuringia, Germany, for 2 days, but did not reside in a wooden area, and was not bitten by ticks. He was vaccinated against yellow fever in 1996 but not vaccinated against TBEV. The patient did not report any consumption of unpasteurized milk products in the month before illness onset.

Physical examination revealed no abnormalities. Laboratory tests showed signs of inflammation: C-reactive protein (CRP): 45 mg/L (norm: <10 mg/L); leukocytes: 10.4 x 109/L (norm: 4–10 mmol/L). A slightly lower haemoglobin (Hb) concentration (7.8 mmol/L; norm: 8.5–11.0 mmol/L) possibly indicative of an infection ongoing for some time. The result of the thorax X-ray examination was normal.

The dehydrated patient was hospitalised with differential diagnosis being gastroenteritis, borreliosis, or a bacterial infection. Ceftriaxone therapy intravenously (2 g per day) was initiated. On day 2, his condition did not improve, and an overt mental slowness became evident as well as a tremor in both hands, with concurrent loss of strength.

Lumbar puncture was performed and cerebrospinal fluid (CSF) analysis revealed leukocytosis (99 x 106/L (norm: <5 x 106/L); 85% mononuclear cells; 15% polynuclear cells (norm: <6%); glucose and protein concentrations of 3.3 mmol/L (norm: 2.2–3.9 mmol/L) and 1,101 mg/L (norm: 250-800 mg/L) respectively. The working diagnosis now was a meningoencephalitis, possibly caused by a virus, or neuroborreliosis. Acyclovir, intravenously 3 mg/kg, 3 times per day, was added to the treatment regimen.

ELISA tests on both CSF and serum did not elicit Borrelia-specific antibodies. Nucleic acid detection of various potential pathogens in the CSF turned out negative (Table 1). Due to a report by the Dutch National Institute for Public Health and the Environment (RIVM), on 30 June 2016, of the first time detection of TBEV in ticks in the Sallandse heuvelrug region [1], serum was investigated for TBEV-specific antibodies. Pending the results, doxycycline, 100 mg twice per day, was added to the regimen, because rickettsiosis could not be excluded at the time. A brain magnetic resonance imaging (MRI) was performed, showing an enlargement and staining of the dura mater, which may suggest viral meningitis.

Table 1
Nucleic acid detection of pathogens in cerebrospinal fluid, tick-borne encephalitis (TBE) case, the Netherlands, June 2016

On day 7, the results of the TBEV serology confirmed the following: anti-TBEV IgM and IgG were detected in serum with the ELISA method, suggesting a recent TBEV infection (Table 2). Also, the CSF turned out positive for anti-TBEV IgG and borderline positive for anti-TBEV IgM. The antibiotics and acyclovir were stopped. By day 9 the patient gradually improved. However, the tinnitus persisted.

Table 2
Tick-borne encephalitis (TBE) virus diagnostic test results, TBE case, the Netherlands, June 2016

The ELISA results were confirmed with a virus neutralisation assay, by the Department of Virology of the Medical University Vienna, Austria. A second serum sample taken on 8 August showed an increase in virus neutralising antibody titres (from 1:10 to 1:480), which is proof of an acute infection.


TBE is a zoonotic infectious disease, caused by TBEV. Natural hosts are small rodents while larger mammals like deer and humans may become accidentally infected. Infection of humans mainly occurs by transmission of the virus through the bite of an infected tick (Ixodes species). The chance of transmission depends on the activity of ticks, and increases during spring. Alternatively, infection may occur by ingestion of milk and milk products from viraemic ruminants [2]. TBE caused by the European subtype TBEV (TBEV-Eu) characteristically has a biphasic course, starting with influenza-like symptoms such as fever, malaise, headache and myalgia (average 2–7 days). After a successive symptom-free interval (average 2–10 days), approximately one third of the cases develop neurological symptoms, varying from mild meningitis to severe encephalitis, with or without myelitis and paralysis of extremities and breathing muscles [3,4].

In Europe, areas of risk for TBE are predominantly situated in central and eastern Europe, and the Baltic and northern countries [5]. In the Netherlands, TBE was only considered as an imported disease until the first case of autochthonous TBE was reported, occurring in June 2016, shortly before our case [6]. In the first case, the virus was recovered and showed strong homology with the common TBEV-Eu strains that cause disease in Europe. The infection likely occurred in a forested area between Driebergen en Maarn, in the province of Utrecht. There was no link to the Sallandse heuvelrug region, in the province of Overijssel, which was at that time the only region in the Netherlands known to harbour TBEV infected ticks. There are currently no proven infections described with the TBE-Eu strain of the Sallandse heuvelrug, which is genetically distinct from the common TBE-Eu strains (data not shown and [6]).


We present a confirmed case of TBE, according to the European Union case definition (symptoms of meningoencephalitis combined with a rise in TBEV-specific antibody titres) [7]. The typical biphasic clinical course in our case fits the diagnosis TBE. Vomiting, a prominent symptom in our case, is usually not described in association with TBE, nor is tinnitus [3,4].

The microbiological diagnosis of TBE is based on serological tests. Because of the strong likelihood of cross reactivity with antibodies against TBEV-related viruses, other flaviviruses, as for instance yellow fever virus, positive ELISA results need to be confirmed with a virus neutralisation assay [8]. In this way, confirmed ELISA results combined with a rise in TBEV-specific antibody titres, make a different explanation for the positive test results, as for instance a past yellow fever vaccination, unlikely.

Chances are high that the TBEV infection was acquired in the Sallandse heuvelrug region. The patient was bitten by a tick in that region during the incubation phase, which ranges from 4 to 28 days (average 7–10 days) [4], and he had neither been in the Utrechtse heuvelrug region, nor in a TBEV-endemic area abroad. His visit to Bad Salzungen was two weeks before the maximum incubation time of 28 days, it lasted only shortly, and was without at-risk activities. Moreover, Bad Salzungen is not regarded one of the risk areas in Germany [9].

For a definite proof that the infection was caused by the TBEV-Eu strain from the Sallandse heuvelrug, nucleic acid sequence analysis of the virus, recovered from the patient or tick, would be required. This is of clinical importance, because the TBEV-Eu strain from the Sallandse heuvelrug genetically diverges from the commonly found TBE-Eu strains, and it is not known whether this strain infects people and causes symptoms. There is 93% homology between the Sallandse heuvelrug TBEV-Eu strain and the prototype TBEV-Eu Neudörfl strain (data not shown), which is found in large parts of Europe. For comparison, the TBEV-Eu strain from the first Dutch TBE case, reported in August 2016, showed 99% homology with this common TBEV-Eu strain [6].

Recovering of nucleic acid sequences was, however, not possible. The aforementioned tick had not been saved, and the chance of detecting the virus in patient materials at the time of neurological symptoms is extremely small [8] (also Table 2). Based on the place of residence and travel history of the patient, it seems however likely that the acquired infection was caused by the Sallandse heuvelrug TBEV-Eu strain because this strain represents the single strain that has been found in this region so far (data not shown).

Although a large national survey is lacking, based on the current knowledge, the percentage of TBEV infected ticks seems to be low (< 0.1% in the Sallandse heuvelrug region). In comparison, the average percentage of ticks in the Netherlands infected with Borrelia burgdorferi was estimated between 15 and 20% [2]. Besides Borrelia burgdorferi and TBEV, ticks in the Netherlands have been shown to harbour other potential human pathogens, like Anaplasma, Rickettsia, Candidatus Neoehrlichia, Babesia spp., and Borrelia miyamotoi, but their clinical relevance is still unclear [10].

Worldwide, TBEV infections have been on the rise in recent years, and endemic areas have been expanding [11]. When and from where TBEV was introduced into the Sallandse heuvelrug area is unclear. Deer from this region were shown to carry TBEV-specific antibodies, in a survey dating from 2010 (data not shown). It is therefore possible that TBEV has been present in the Netherlands for already some years, and TBEV infections may have been overlooked. The majority of TBEV infections do not lead to TBE symptoms. This suggests that for the two identified autochthonous TBE cases in the Netherlands, a larger number of (undiagnosed) TBEV infections might be expected.

Currently, no specific therapy that targets TBEV exists. Effective vaccines against TBE are available, and are on the market since the 1980s. No advice on TBE vaccination exists for the Netherlands [2]. The risk of TBEV infection in the Netherlands is currently being assessed by the RIVM.


This is the first described case of TBE associated with the Sallandse heuvelrug region, where TBEV is endemic in ticks. Yet, definite proof that the infection was caused by the specific TBEV-Eu strain from that region is lacking. Being the second autochthonous TBE case in the Netherlands, however, it provides more evidence for endemic TBEV transmission in this country. With the new tick season approaching, clinicians in the Netherlands should consider TBE in the differential diagnosis of patients with meningoencephalitis symptoms especially after a tick bite, even if there has been no recent travel to a known TBE-endemic country.


We would like to thank Dr H. Holzmann at the Medical University Vienna, Austria, for performing the virus neutralisation assay.


Conflict of interest: None declared.

Contributed by

Authors’ contributions: ACG Weststrate and F Geeraedts wrote the initial drafts of this article. All authors were involved in correcting the paper on critical points concerning their specific field of expertise and involvement in this case. D. Knapen, GD Laverman, B Schot, JJW Prick were responsible for the clinical management, SA Spit for providing detailed socio-geographical information; B Rockx, J Reimerink and F Geeraedts were responsible for microbiological laboratory testing.


1. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Tekenencefalitisvirus aangetroffen in Nederlandse teken. [Tick-borne encephalitis virus found in Dutch ticks]. [Accessed 14 March 2016]. Dutch. Available from:
2. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). LCI-richtlijn Tekenencefalitis. [National Coordination Centre for Communicable Diseases Control guidelines on tick-borne encephalitis]. Bilthoven: RIVM. [Accessed 15 Nov 2016]. Dutch. Available from:
3. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-71. 10.1016/S0140-6736(08)60800-4 [PubMed] [Cross Ref]
4. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain. 1999;122(Pt 11):2067-78. 10.1093/brain/122.11.2067 [PubMed] [Cross Ref]
5. European Centre for Disease Prevention and Control (ECDC). Technical Report: Epidemiological situation of tick-borne encephalitis in the European Union and European Free Trade Association countries, September 2012. Stockholm: ECDC; [Accessed 14 March 2016]. Available from:
6. de Graaf JA, Reimerink JH, Voorn GP, Bij de Vaate EA, de Vries A, Rockx B, et al. First human case of tick-borne encephalitis virus infection acquired in the Netherlands, July 2016. Euro Surveill. 2016;21(33):21. 10.2807/1560-7917.ES.2016.21.33.30318 [PMC free article] [PubMed] [Cross Ref]
7. European Commission. Commission Implementing Decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document C(2012) 5538). Official Journal of the European Union. Luxembourg: Publications Office of the European Union. 27.9.2012:L 262/34. Available from:
8. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine. 2003;21(Suppl 1):S36-40. 10.1016/S0264-410X(02)00819-8 [PubMed] [Cross Ref]
9. Robert Koch-Institut (RKI). FSME-Risikogebiete in Deutschland. [Risk areas of tick-borne encephalitis in Germany]. Berlin: RKI; 9 May 2016. German. Available from:
10. Jahfari S, Hofhuis A, Fonville M, van der Giessen J, van Pelt W, Sprong H. Molecular Detection of Tick-Borne Pathogens in Humans with Tick Bites and Erythema Migrans, in the Netherlands. PLoS Negl Trop Dis. 2016;10(10):e0005042. 10.1371/journal.pntd.0005042 [PMC free article] [PubMed] [Cross Ref]
11. Kunze U. The International Scientific Working Group on Tick-Borne Encephalitis (ISW TBE): Review of 17 years of activity and commitment. Ticks Tick Borne Dis. 2016;7(3):399-404. 10.1016/j.ttbdis.2015.12.018 [PubMed] [Cross Ref]

Articles from Eurosurveillance are provided here courtesy of European Centre for Disease Prevention and Control